Immunochemical assay method

Claim 2

In a quantitative immunoassay for the presence of a target in a sample comprising producing a mixture of the sample, a known quantity of an antibody which is immunologically specific for the target, and a known quantity of a standard immunologically homologous to the target, so as to bind with said antibody competitively, one of said antibody and said standard having a covalently bonded derivative capable of emitting radiation from the mixture, providing for competitive antibody binding to take place and measuring the radiation emitted from a portion of the derivative, which radiation measurement is indicative of the relative proportions of target and standard binding with the antibody, and thus the amount of target present, the improvement comprising employing as the antibody, antibody raised by and specific to the hapten portion of a synthetic antigen comprising a plurality of hapten moieties covalently bound to a carrier, said moieties being immunologically homologous with the target and the hapten being bound by a --N═N-- group coupled directly to an otherwise unsubstituted ring atom of the hapten.

Claim 3

The immunoassay of claim 1 wherein the target is a compound selected from the group consisting of estrone, estradiol, estriol, morphine, tetrahydrocannabinol, amphetamine, epinephrine, norepinephrine, a diazepoxide, angiotensin, thyroxin, aldosterone, thyrotropic release hormone, luteinizing hormone, adrenocorticotropin, and testosterone.

Claim 4

The immunoassay of claim 1 wherein the carrier is a protein selected from the class consisting of keyhole limpet hemocyanin, bovine serum albumin, and human gamma globulin.

Claim 5

In a quantitative immunoassay for the presence of a target in a sample comprising producing a mixture of the sample, a known quantity of an antibody which is immunologically specific for the target, and a known quantity of a standard immunologically homologous to the target, so as to bind with said antibody competitively, one of said antibody and said standard having a covalently bonded derivative capable of emitting radiation from the mixture, providing for competitive antibody binding to take place and measuring the radiation emitted from a portion of the derivative, which radiation measurement is indicative of the relative proportions of target and standard binding with the antibody, and thus the amount of target present, the improvement comprising employing as the antibody, antibody raised by and specific to an antigen of formula: carrier--Ar--N═N--hapten!.sub.n in which "carrier" is an immunogenic carrier; Ar is an arylene radical to which the immunogenic carrier is linked through a connective group; the hapten is immunologically homologous to the target when coupled to the carrier through the arylene and azo groups, and has a ring with an unsubstituted ring atom bonded directly to the azo group; and n is an integer not exceeding the number of functional moieties available on the carrier to partake in forming said connective group.

Claim 6

In a quantitative immunoassay for the presence of a target in a sample comprising producing a mixture of the sample, a known quantity of an antibody which is immunologically specific for the target, and a known quantity of a standard immunologically homologous to the target, so as to bind with said antibody competitively, one of said antibody and said standard having a covalently bonded derivative capable of emitting radiation from the mixture, providing for competitive antibody binding to take place and measuring the radiation emitted from a portion of the derivative, which radiation measurement is indicative of the relative proportions of target and standard binding with the antibody, and thus the amount of target present, the improvement comprising employing as the antibody, antibody raised by and specific to an antigen of formula: carrier--Ar--N═N--hapten!.sub.n in which "carrier" is an immunogenic carrier; Ar is an arylene radical to which the immunogenic carrier is linked through a connective group; the hapten is immunologically homologous to the target when coupled to the carrier through the arylene and azo groups, and has a ring with an unsubstituted ring atom bonded directly to the azo group; and n is an integer not exceeding the number of functional moieties available on the carrier to partake in forming said connective group.

Claim 7

The immunoassay of claim 4 wherein the target is a compound selected from the group consisting of estrone, estradiol, estriol, morphine, tetrahydrocannabinol, amphetamine, epinephrine, norepinephrine, a diazepoxide, angiotensin, thyroxin, aldosterone, thyrotropic release hormone, luteinizing hormone, adrenocorticotropin, and testosterone.

Claim 8

The immunoassay of claim 4 wherein the carrier is a protein selected from the class consisting of keyhole limpet hemocyanin, bovine serum albumin, and human gamma globulin.

Claim 9

The immunoassay of claim 1 wherein the synthetic antigen employed is one with a purity of at least 98%.

Claim 10

The immunoassay of claim 1 wherein the synthetic antigen is an antigen prepared by a method including coupling of an immunogenic carrier with an azo-hapten compound and in which said azo-hapten compound has a purity of at least 98%.

Claim 11

The immunoassay of claim 4 wherein the synthetic antigen employed is one with a purity of at least 98%.

Claim 12

In a quantitative radioimmune assay for the presence of a target in a sample comprising providing a mixture of the sample, a known quantity of a antibody which is immunologically specific for the target, and a known quantity of a standard immunologically homologous to the target so as to bind with said antibody competitively, one of the antibody and the standard having a covalently bonded radioisotopic derivative, providing for competitive antibody binding, separating bound derivative compound from unbound derivative compound and measuring the radiation emanating from one of said separated and unseparated derivative compounds to indicate the proportion of antibody bound to the standard, and thus the amount of target present, the improvement which comprises employing as the antibody, antibody raised by and specific to the hapten portion of a synthetic antigen comprising a plurality of hapten moieties covalently bound to a carrier, said moieties being immunologically homologous with the target and the hapten being bound by a --N═N-- group coupled directly to an otherwise unsubstituted ring atom of the hapten.

Claim 13

In a quantitative radioimmune assay for the presence of a target in a sample comprising providing a mixture of the sample, a known quantity of a antibody which is immunologically specific for the target, and a known quantity of a standard immunologically homologous to the target so as to bind with said antibody competitively, one of the antibody and the standard having a covalently bonded radioisotopic derivative, providing for competitive antibody binding, separating bound derivative compound from unbound derivative compound and measuring the radiation emanating from one of said separated and unseparated derivative compounds to indicate the proportion of antibody bound to the standard, and thus the amount of target present, the improvement which comprises employing as the antibody, antibody raised by and specific to the hapten portion of a synthetic antigen comprising a plurality of hapten moieties covalently bound to a carrier, said moieties being immunologically homologous with the target and the hapten being bound by a --N═N-- group coupled directly to an otherwise unsubstituted ring atom of the hapten.

Claim 14

The immunoassay of claim 10 wherein the target is a compound selected from the group consisting of estrone, estradiol, estriol, morphine, tetrahydrocannabinol, amphetamine, epinephrine, norepinephrine, a diazepoxide, angiotensin, thyroxin, aldosterone, thyrotropic release hormone, luteinizing hormone, adrenocorticotropin, and testosterone.

Claim 15

The immunoassay of claim 10 wherein the carrier is a protein selected from the class consisting of keyhole limpet hemocyanin, bovine serum albumin, and human gamma globulin.

Claim 16

The immunoassay of claim 10 wherein the synthetic antigen employed is one with a purity of at least 98%.

Claim 17

The immunoassay of claim 10 wherein the synthetic antigen is an antigen prepared by a method including coupling of an immunogenic carrier with an azo-hapten compound and in which said azo-hapten compound has a purity of at least 98%.

Claim 18

The radioimmune assay of claim 10 wherein the separation is a phase separation, one of the standard and the antibody carrying said radioisotopic derivative and the other being insolubilized.

Claim 19

The radioimmune assay of claim 10 wherein the radioisotopic derivative is covalently bound to one of the antibody and the carrier portion of the standard, the standard being a hapten-carrier conjugate.

Claim 20

In a quantitative radioimmune assay for the presence of a target in a sample comprising providing a mixture of the sample, a known quantity of an antibody which is immunologically specific for the target, and a known quantity of a standard immunologically homologous to the target so as to bind with said antibody competitively, one of the antibody and the standard having a covalently bonded radioisotopic derivative, providing for competitive antibody binding, separating bound derivative compound from unbound derivative compound and measuring the radiation emanating from one of said separated and unseparated derivative compounds to indicate the proportion of antibody bound to the standard, and thus the amount of target present, the improvement which comprises employing as the antibody, antibody raised by and specific to an antigen of formula: carrier --Ar--N═N--hapten!.sub.n in which "carrier" is an immunogentic carrier; Ar is an arylene radical to which the immunogenic carrier is linked through a connective group; the hapten is immunologically homologous to the target when coupled to the carrier through the arylene and azo groups, and has a ring with an unsubstituted ring atom bonded directly to the azo group; and n is an integer not exceeding the number of functional moieties available on the carrier to partake in forming said connective group.

Claim 21

In a quantitative radioimmune assay for the presence of a target in a sample comprising providing a mixture of the sample, a known quantity of an antibody which is immunologically specific for the target, and a known quantity of a standard immunologically homologous to the target so as to bind with said antibody competitively, one of the antibody and the standard having a covalently bonded radioisotopic derivative, providing for competitive antibody binding, separating bound derivative compound from unbound derivative compound and measuring the radiation emanating from one of said separated and unseparated derivative compounds to indicate the proportion of antibody bound to the standard, and thus the amount of target present, the improvement which comprises employing as the antibody, antibody raised by and specific to an antigen of formula: carrier --Ar--N═N--hapten!.sub.n in which "carrier" is an immunogentic carrier; Ar is an arylene radical to which the immunogenic carrier is linked through a connective group; the hapten is immunologically homologous to the target when coupled to the carrier through the arylene and azo groups, and has a ring with an unsubstituted ring atom bonded directly to the azo group; and n is an integer not exceeding the number of functional moieties available on the carrier to partake in forming said connective group.

Claim 22

The immunoassay of claim 17 wherein the target is a compound selected from the group consisting of estrone, estradiol, estriol, morphine, tetrahydrocannabinol, amphetamine, epinephrine, norepinephrine, a diazepoxide, angiotensin, thyroxin, aldosterone, thyrotropic release hormone, luteinizing hormone, adrenocorticotropin, and testosterone.

Claim 23

The immunoassay of claim 17 wherein the carrier is a protein selected from the class consisting of keyhole limpet hemocyanin, bovine serum albumin, and human gamma globulin.

Claim 24

The immunoassay of claim 17 wherein the synthetic antigen is an antigen prepared by a method including coupling of an immunogenic carrier with an azo-hapten compound and in which said azo-hapten compound has a purity of at least 98%.

Claim 25

The radioimmune assay of claim 17 wherein the separation is a phase separation, one of the standard and the antibody carrying said adioisotopic derivative and the other being insolubilized.

Claim 26

The radioimmune assay of claim 17 wherein the radioisotopic derivative is covalently bound to one of the antibody and the carrier portion of the standard, the standard being a hapten-carrier conjugate.